Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study

被引：1
|
作者：
Simonelli, M. [1 ]
Lorusso, D. [2 ]
Homicsko, K. [3 ,4 ]
Seguy, F. [5 ]
Kinder, M. [6 ]
Liu, Q. [7 ]
Croft, E. [8 ]
Kitano, S. [9 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol, Rozzano, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS Rome & H, Gynaecol Oncol Unit, Milan, Italy
[3] UNIL, Ludiwg Inst Canc Res, Oncol Dept, Lausanne, Switzerland
[4] CHU Vaudois, Lausanne, Switzerland
[5] Incyte Biosci Int Sarl, Clin Dev, Morges, Switzerland
[6] Incyte Corp, Translat Sci, Wilmington, DE USA
[7] Incyte Corp, Biostats, Wilmington, DE USA
[8] Incyte Corp, Early Clin Dev, Wilmington, DE USA
[9] Canc Inst Hosp JFCR, Dept Adv Med Dev, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.684
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617MO
引用
收藏
页码：S495 / S495
页数：1
相关论文
共 50 条
  • [31] A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors
    Ma, Yuxiang
    Fang, Wenfeng
    Zhao, Hongyun
    Bathena, Sai Praneeth
    Tendolkar, Amol
    Sheng, Jennifer
    Zhang, Li
    ONCOLOGIST, 2021, 26 (04): : E549 - E566
  • [32] Safety and tolerability of the olaparib tablet formulation in Japanese patients (pts) with advanced solid tumors (ASTs)
    Takahashi, Yasuo
    Fujikawa, Koshi
    Sagawa, Tamotsu
    Yonemori, Kan
    Tamura, Kenji
    Kodaira, Makoto
    Esaki, Taito
    Shirakawa, Tsuyoshi
    Hirai, Fumihiko
    Yokoi, Yuki
    Kawata, Toshio
    Hatano, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors
    Kabir Mody
    Aaron S. Mansfield
    Lalitha Vemireddy
    Peter Nygren
    Joachim Gulbo
    Mitesh Borad
    Investigational New Drugs, 2019, 37 : 684 - 692
  • [34] A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors
    Mody, Kabir
    Mansfield, Aaron S.
    Vemireddy, Lalitha
    Nygren, Peter
    Gulbo, Joachim
    Borad, Mitesh
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 684 - 692
  • [35] A PHASE 1 STUDY EXPLORING THE SAFETY AND TOLERABILITY OF THE SMALL MOLECULE PD-L1 INHIBITOR, INCB086550, IN PATIENTS WITH SELECT ADVANCED TUMORS
    Le Tourneau, Christophe
    Piha-Paul, Sarina
    Prenen, Hans
    Delafontaine, Brant
    Pinato, David
    Santoro, Armando
    Kristeleit, Rebecca
    Spencer, Kristen
    Gangadhar, Tara
    Burris, Howard
    Kotecki, Nuria
    Basu, Bristi
    Graham, Donna
    Di Giacomo, Anna Maria
    Sahebjam, Solmaz
    Di Nicola, Massimo
    Gomez-Roca, Carlos
    Tomasini, Pascale
    Ascierto, Paolo
    Curigliano, Giuseppe
    Karasic, Thomas
    Geschwindt, Ryan
    Daniel, Jeannie
    Van Cutsem, Eric
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A805 - A805
  • [36] A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors
    Tolcher, A.
    Do, K. T.
    di Tomaso, E.
    Waters, N.
    Stephens, K.
    Roth, D. A.
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
    J. R. Infante
    R. Kurzrock
    J. Spratlin
    H. A. Burris
    S. G. Eckhardt
    J. Li
    K. Wu
    J. M. Skolnik
    L. Hylander-Gans
    A. Osmukhina
    D. Huszar
    R. S. Herbst
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 165 - 172
  • [38] A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
    Infante, J. R.
    Kurzrock, R.
    Spratlin, J.
    Burris, H. A.
    Eckhardt, S. G.
    Li, J.
    Wu, K.
    Skolnik, J. M.
    Hylander-Gans, L.
    Osmukhina, A.
    Huszar, D.
    Herbst, R. S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 165 - 172
  • [39] Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs)
    Hamberg, P.
    Steeghs, N.
    Loos, W. J.
    van der Biessen, D. J.
    den Hollander, M. A.
    Tascilar, M.
    Verweij, J.
    Gelderblom, H.
    Sleijfer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] A phase I safety, tolerability5 and pharmacokinetic study of enzastaurin combined with advanced solid tumors
    Carnidge, D. Ross
    Eckhardt, S. Gail
    Gore, Lia
    O'Bryant, Cindy L.
    Leong, Stephen
    Basche, Michelle
    Holden, Scott N.
    Musib, Luna
    Baldwin, John
    Darstein, Christelle
    Thornton, Donald
    Finn, Richard S.
    Britten, Carolyn D.
    ANTI-CANCER DRUGS, 2008, 19 (01) : 77 - 84
12345